MAP2K7 and acute lymphoblastic leukemia: In human T-ALLs, upregulation of ERK1/2 signaling was found in 38% of T-ALL patients [57] and MEK/ERK can be activated due to RAS mutations, found in ~10% of T-ALL patients [58].